Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma
Launched by TAKEDA · Mar 16, 2021
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
The drug being tested in this study is called cabozantinib tablets. This tablet is being tested to treat people who have radically unresectable or metastatic renal cell carcinoma.
This study is an observational (non-interventional) study and will look at occurrence of adverse drug reactions (or adverse events) of cabozantinib tablets in the routine clinical setting. The planned number of observed patients will be approximately 300.
This multi-center observational trial will be conducted in Japan.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with radically unresectable or metastatic renal cell carcinoma who do not meet the following exclusion criterion are eligible.
- Exclusion Criteria:
- • A patient who has a history of hypersensitivity to any component of cabozantinib.
About Takeda
Takeda Pharmaceutical Company Limited is a global, research-driven biopharmaceutical organization committed to advancing patient care through innovative therapies. Founded in 1781 and headquartered in Osaka, Japan, Takeda focuses on key therapeutic areas including oncology, gastroenterology, neuroscience, and rare diseases. With a strong emphasis on research and development, Takeda leverages cutting-edge science and technology to deliver transformative medicines that address unmet medical needs. The company is dedicated to sustainability and ethical practices, ensuring that its clinical trials uphold the highest standards of safety and efficacy while fostering collaboration with healthcare professionals and communities worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo, , Japan
Patients applied
Trial Officials
Study Director
Study Director
Takeda
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials